Sponsor: 
Sanofi-Aventis Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Combination vaccines

Registered as a booster in people aged ≥4 years.

dTpa-IPV — diphtheria-tetanus-acellular pertussis-inactivated poliovirus combination vaccine (reduced antigen formulation)

Each 0.5 mL monodose vial or pre-filled syringe contains:

  • ≥2 IU diphtheria toxoid
  • ≥20 IU tetanus toxoid
  • 2.5 µg pertussis toxoid
  • 5 µg filamentous haemagglutinin
  • 3 µg pertactin
  • 5 µg pertussis fimbriae types 2 and 3
  • 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
  • 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
  • 32 D-antigen units inactivated poliovirus type 3 (Saukett)
  • 0.33 mg aluminium as aluminium phosphate
  • 0.6% v/v phenoxyethanol

Also contains traces of:

  • formaldehyde
  • glutaraldehyde
  • polysorbate 80
  • polymyxin
  • neomycin
  • streptomycin

The product information and consumer medicine information for Adacel Polio have more details.

Audience: 
Infants and children
Previous

Adacel

Next

ADT Booster

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018

Definitions

dTpa
diphtheria-tetanus-acellular pertussis vaccine, reduced antigen content formulation
IPV
inactivated poliomyelitis vaccine
IU
international units